Abstract
Alzheimer’s disease (AD) is an irreversible multifaceted neurodegenerative disorder that gradually degrades neuronal cells. Presently, it is the most common reason for the memory loss and dementia in older individuals. It is patho-physiologically described by extracellular amyloid beta (Aβ) deposition, intracellular neurofibrillary tangles (NFTs) retention, neuronal decline, and neurotransmitter system derangement. Various receptors such as nicotinic acetylcholine, N-methyl-D-aspartate, insulin, serotonin, adenosine, and histamine are actively involved in the physiological progression of AD. Till date memantine and only four other acetylcholinesterase inhibitors have been approved for the treatment of AD by US Food and Drug Administration (US-FDA). Hence, there is a critical need to explore and develop novel and helpful management systems which could specifically target different receptors involved in AD progression. We believe that these receptors targeting will either impede the disease onset or slow down its pathogenesis. In the present review, we tried to uncover some receptors that could be blocked by novel inhibitors and ultimately used for the therapeutic management of AD.
Keywords: Alzheimer's disease, Nicotinic acetylcholine receptors, N-methyl-D-aspartate receptor, Insulin receptor, Adenosine receptor.
Current Topics in Medicinal Chemistry
Title:Elucidating Treatment of Alzheimer's Disease via Different Receptors
Volume: 17 Issue: 12
Author(s): Badar ul Islam, Mohd Shahnawaz Khan, Nasimudeen R. Jabir, Mohammad Amjad Kamal and Shams Tabrez
Affiliation:
Keywords: Alzheimer's disease, Nicotinic acetylcholine receptors, N-methyl-D-aspartate receptor, Insulin receptor, Adenosine receptor.
Abstract: Alzheimer’s disease (AD) is an irreversible multifaceted neurodegenerative disorder that gradually degrades neuronal cells. Presently, it is the most common reason for the memory loss and dementia in older individuals. It is patho-physiologically described by extracellular amyloid beta (Aβ) deposition, intracellular neurofibrillary tangles (NFTs) retention, neuronal decline, and neurotransmitter system derangement. Various receptors such as nicotinic acetylcholine, N-methyl-D-aspartate, insulin, serotonin, adenosine, and histamine are actively involved in the physiological progression of AD. Till date memantine and only four other acetylcholinesterase inhibitors have been approved for the treatment of AD by US Food and Drug Administration (US-FDA). Hence, there is a critical need to explore and develop novel and helpful management systems which could specifically target different receptors involved in AD progression. We believe that these receptors targeting will either impede the disease onset or slow down its pathogenesis. In the present review, we tried to uncover some receptors that could be blocked by novel inhibitors and ultimately used for the therapeutic management of AD.
Export Options
About this article
Cite this article as:
ul Islam Badar, Khan Shahnawaz Mohd, Jabir R. Nasimudeen, Kamal Amjad Mohammad and Tabrez Shams, Elucidating Treatment of Alzheimer's Disease via Different Receptors, Current Topics in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1568026617666170103163715
DOI https://dx.doi.org/10.2174/1568026617666170103163715 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets When Nutraceuticals Reinforce Drugs Side Effects: A Case Report
Current Drug Safety Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research The Role of Malnutrition in Older Persons with Mobility Limitations
Current Pharmaceutical Design There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimer’s Disease?
Current Alzheimer Research Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry Disturbed Sleep Patterns in Elders with Mild Cognitive Impairment: The Role of Memory Decline and ApoE ε 4 Genotype
Current Alzheimer Research Recent Advances and Patents on Mechanical Circulatory Support Devices
Recent Patents on Biomedical Engineering (Discontinued) Perspectives on Therapeutic Target for Multiple System Atrophy
Recent Patents on Regenerative Medicine Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design BioArena Studies: Unique Function of Endogenous Formaldehyde and Ozone in the Antibiotic Effect – A Review
Medicinal Chemistry Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Older Australians: Structural barriers to learning in later life
Current Aging Science A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Comparison of Changes in Cognitive Functions of Post-stroke Patients with the Computer-based Cognitive Intervention (PABLO System) and Conventional Cognitive Intervention (Paper-pencil Method)
Current Psychiatry Research and Reviews Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice
Current Alzheimer Research